Coherus BioSciences Inc
NASDAQ:CHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Coherus BioSciences Inc
Non-Reccuring Items
Coherus BioSciences Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Coherus BioSciences Inc
NASDAQ:CHRS
|
Non-Reccuring Items
-$8.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Coherus BioSciences Inc
Glance View
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
See Also
What is Coherus BioSciences Inc's Non-Reccuring Items?
Non-Reccuring Items
-8.4m
USD
Based on the financial report for Dec 31, 2025, Coherus BioSciences Inc's Non-Reccuring Items amounts to -8.4m USD.
What is Coherus BioSciences Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-11%
Over the last year, the Non-Reccuring Items growth was 68%. The average annual Non-Reccuring Items growth rates for Coherus BioSciences Inc have been -11% over the past three years .
